A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
Status:
Not yet recruiting
Trial end date:
2023-11-23
Target enrollment:
Participant gender:
Summary
The primary objective of this phase I study is to evaluate the safety and potential efficacy
and to determine the recommended phase 2 dose (RP2D) of IBI325 combined with Sintilimab in
patients with advanced solid tumors